Adverum Bio (ADVM) Stock Forecast, Price Target & Predictions


OverviewOwnershipFinancialsChart

ADVM Stock Forecast


Adverum Bio stock forecast is as follows: an average price target of $15.50 (represents a 109.18% upside from ADVM’s last price of $7.41) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.

ADVM Price Target


The average price target for Adverum Bio (ADVM) is $15.50 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $28.00 to $2.00. This represents a potential 109.18% upside from ADVM's last price of $7.41.

ADVM Analyst Ratings


Buy

According to 2 Wall Street analysts, Adverum Bio's rating consensus is 'Buy'. The analyst rating breakdown for ADVM stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 1 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Adverum Bio Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 14, 2024Francois BriseboisOppenheimer$28.00$7.81258.51%277.87%
Sep 20, 2024Graig SuvannavejhMizuho Securities$20.00$7.50166.67%169.91%
Aug 13, 2024Luca IssiRBC Capital$12.00$6.6480.72%61.94%
Nov 11, 2022-Chardan Capital$2.00$0.71183.65%-73.01%
Row per page
Go to

The latest Adverum Bio stock forecast, released on Oct 14, 2024 by Francois Brisebois from Oppenheimer, set a price target of $28.00, which represents a 258.51% increase from the stock price at the time of the forecast ($7.81), and a 277.87% increase from ADVM last price ($7.41).

Adverum Bio Price Target by Period


1M3M12M
# Anlaysts133
Avg Price Target$28.00$20.00$20.00
Last Closing Price$7.41$7.41$7.41
Upside/Downside277.87%169.91%169.91%

In the current month, the average price target of Adverum Bio stock is $28.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 277.87% increase as opposed to Adverum Bio's last price of $7.41. This month's average price target is up 40.00% compared to last quarter, and up 40.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Oct 03, 2024OppenheimerOutperformOutperformHold
Aug 13, 2024RBC CapitalSector PerformSector PerformHold
Jun 25, 2024Oppenheimer-OutperformInitialise
Nov 11, 2022RBC CapitalSector PerformSector PerformHold
Row per page
Go to

Adverum Bio's last stock rating was published by Oppenheimer on Oct 03, 2024. The company gave ADVM a "Outperform" rating, the same as its previous rate.

Adverum Bio Financial Forecast


Adverum Bio Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17Mar 16Mar 15Sep 14
Revenue--------$7.50M-----$250.00K--$216.00K$462.00K$265.00K$203.00K$204.00K
Avg Forecast----$131.25K$125.00K$106.00K$127.50K$92.00K$76.67K$76.67K$76.67K$108.57K$253.33K$265.00K$377.50K$320.00K$208.80K$376.89K$181.31K$213.68K$85.68K
High Forecast----$131.25K$125.00K$106.00K$127.75K$92.00K$76.67K$76.67K$76.67K$108.57K$253.33K$265.00K$377.50K$320.00K$250.56K$452.27K$217.58K$256.42K$102.82K
Low Forecast----$131.25K$125.00K$106.00K$127.25K$92.00K$76.67K$76.67K$76.67K$108.57K$253.33K$265.00K$377.50K$320.00K$167.04K$301.51K$145.05K$170.95K$68.54K
# Analysts----131144644743791412911
Surprise %--------81.52%-----0.94%--1.03%1.23%1.46%0.95%2.38%

Adverum Bio's average Quarter revenue forecast for Mar 24 based on 1 analysts is $127.50K, with a low forecast of $127.25K, and a high forecast of $127.75K. ADVM's average Quarter revenue forecast represents a -98.30% decrease compared to the company's last Quarter revenue of $7.50M (Mar 21).

Adverum Bio EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17Mar 16Mar 15Sep 14
# Analysts----131144644743791412911
EBITDA--------$-27.27M$-36.55M$-26.58M$-27.90M$-22.31M$-20.19M$-15.20M$-13.99M$-13.52M$-16.74M$-15.58M$-15.07M$-9.39M$-8.21M
Avg Forecast----$-26.25K$-25.00K$-21.20K$-25.50K$-33.73M$-15.33K$-15.33K$-15.33K$-19.76M$-50.67K$-53.00K$-75.50K$-16.93M$-16.16M$-12.06M$-8.93M$-9.86M$-3.44M
High Forecast----$-26.25K$-25.00K$-21.20K$-25.45K$-26.98M$-15.33K$-15.33K$-15.33K$-15.80M$-50.67K$-53.00K$-75.50K$-13.54M$-12.93M$-9.65M$-7.14M$-7.89M$-2.75M
Low Forecast----$-26.25K$-25.00K$-21.20K$-25.55K$-40.47M$-15.33K$-15.33K$-15.33K$-23.71M$-50.67K$-53.00K$-75.50K$-20.31M$-19.40M$-14.48M$-10.71M$-11.83M$-4.13M
Surprise %--------0.81%2384.07%1733.78%1819.80%1.13%398.51%286.85%185.37%0.80%1.04%1.29%1.69%0.95%2.39%

undefined analysts predict ADVM's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Adverum Bio's previous annual EBITDA (undefined) of $NaN.

Adverum Bio Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17Mar 16Mar 15Sep 14
# Analysts----131144644743791412911
Net Income--------$-28.44M$-37.63M$-27.77M$-29.20M$-22.91M$-18.93M$-16.12M$-14.95M$-14.49M$-17.20M$-16.10M$-15.39M$-9.51M$-8.26M
Avg Forecast$-25.02M$-27.59M$-30.58M$-28.36M$-27.49M$-27.26M$-30.60M$-29.28M$-35.17M$-67.39M$-71.59M$-60.24M$-19.51M$-61.17M$-55.26M$-61.30M$-16.64M$-16.61M$-12.46M$-9.12M$-9.98M$-3.46M
High Forecast$-25.02M$-27.59M$-30.58M$-28.36M$-27.49M$-20.90M$-30.60M$-29.28M$-28.14M$-67.39M$-71.59M$-60.24M$-15.61M$-61.17M$-55.26M$-61.30M$-13.31M$-13.29M$-9.97M$-7.29M$-7.99M$-2.77M
Low Forecast$-25.02M$-27.59M$-30.58M$-28.36M$-27.49M$-30.44M$-30.60M$-29.28M$-42.21M$-67.39M$-71.59M$-60.24M$-23.42M$-61.17M$-55.26M$-61.30M$-19.96M$-19.93M$-14.96M$-10.94M$-11.98M$-4.15M
Surprise %--------0.81%0.56%0.39%0.48%1.17%0.31%0.29%0.24%0.87%1.04%1.29%1.69%0.95%2.39%

Adverum Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ADVM's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Adverum Bio SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17Mar 16Mar 15Sep 14
# Analysts----131144644743791412911
SG&A--------$16.16M$13.65M$11.35M$10.60M$9.04M$8.28M$7.39M$7.13M$5.58M$5.37M$7.99M$8.32M$4.14M$2.40M
Avg Forecast----$3.58M$3.41M$2.89M$3.48M$2.51M$2.09M$2.09M$2.09M$2.96M$6.91M$7.23M$10.30M$8.73M$5.70M$10.28M$4.95M$5.83M$2.34M
High Forecast----$3.58M$3.41M$2.89M$3.48M$2.51M$2.09M$2.09M$2.09M$2.96M$6.91M$7.23M$10.30M$8.73M$6.83M$12.34M$5.94M$6.99M$2.80M
Low Forecast----$3.58M$3.41M$2.89M$3.47M$2.51M$2.09M$2.09M$2.09M$2.96M$6.91M$7.23M$10.30M$8.73M$4.56M$8.22M$3.96M$4.66M$1.87M
Surprise %--------6.44%6.53%5.43%5.07%3.05%1.20%1.02%0.69%0.64%0.94%0.78%1.68%0.71%1.03%

Adverum Bio's average Quarter SG&A projection for Mar 24 is $3.48M, based on 1 Wall Street analysts, with a range of $3.47M to $3.48M. The forecast indicates a -78.48% fall compared to ADVM last annual SG&A of $16.16M (Mar 21).

Adverum Bio EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17Mar 16Mar 15Sep 14
# Analysts----131144644743791412911
EPS--------$-0.29$-0.38$-0.31$-0.36$-0.31$-0.26$-0.25$-0.23$-0.23$-0.30$-0.38$-0.57$-0.38$-0.37
Avg Forecast$-1.20$-1.32$-1.47$-1.36$-1.32$-1.31$-1.47$-1.40$-3.81$-3.23$-3.43$-2.89$-2.73$-2.93$-2.65$-2.94$-2.68$-0.28$-0.24$-0.23$-0.42$-0.09
High Forecast$-1.20$-1.32$-1.47$-1.36$-1.32$-1.00$-1.47$-1.40$-3.81$-3.23$-3.43$-2.89$-2.73$-2.93$-2.65$-2.94$-2.68$-0.22$-0.19$-0.18$-0.34$-0.07
Low Forecast$-1.20$-1.32$-1.47$-1.36$-1.32$-1.46$-1.47$-1.40$-3.81$-3.23$-3.43$-2.89$-2.73$-2.93$-2.65$-2.94$-2.68$-0.34$-0.29$-0.28$-0.50$-0.11
Surprise %--------0.08%0.12%0.09%0.12%0.11%0.09%0.09%0.08%0.09%1.07%1.58%2.48%0.90%4.08%

According to undefined Wall Street analysts, Adverum Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ADVM previous annual EPS of $NaN (undefined).

Adverum Bio Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
BCELAtreca$0.09$4.004344.44%Buy
ONCTOncternal Therapeutics$1.50$28.001766.67%Buy
PASGPassage Bio$0.63$6.00852.38%Buy
QUREuniQure$5.86$53.67815.87%Buy
KODKodiak Sciences$3.84$31.60722.92%Buy
ANTXAN2 Therapeutics$1.08$8.75710.19%Buy
AVTEAerovate Therapeutics$2.79$13.00365.95%Hold
SLDBSolid Biosciences$5.75$17.50204.35%Buy
FIXXQ32 Bio$0.93$2.70190.32%Buy
ACRVAcrivon Therapeutics$8.01$22.00174.66%Buy
RCKTRocket Pharmaceuticals$16.98$45.00165.02%Buy
RZLTRezolute$5.50$13.50145.45%Buy
KZRKezar Life Sciences$7.21$17.50142.72%Buy
STOKStoke Therapeutics$12.86$30.60137.95%Buy
AFMDAffimed$3.26$7.50130.06%Buy
ADVMAdverum Bio$7.41$15.50109.18%Buy
ADAGAdagene$3.00$5.0066.67%Buy
MREOMereo BioPharma Group$4.28$6.7557.71%Buy
MGTXMeiraGTx$5.81$9.0054.91%Buy
GLMDGalmed Pharmaceuticals$3.24$5.0054.32%Buy
ABSIAbsci$3.92$6.0053.06%Buy
RYTMRhythm Pharmaceuticals$49.01$48.60-0.84%Buy

ADVM Forecast FAQ


Yes, according to 2 Wall Street analysts, Adverum Bio (ADVM) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 50.00% of ADVM's total ratings.

Adverum Bio (ADVM) average price target is $15.5 with a range of $2 to $28, implying a 109.18% from its last price of $7.41. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for ADVM stock, the company can go up by 109.18% (from the last price of $7.41 to the average price target of $15.5), up by 277.87% based on the highest stock price target, and down by -73.01% based on the lowest stock price target.

ADVM's average twelve months analyst stock price target of $15.5 supports the claim that Adverum Bio can reach $11 in the near future.

1 Wall Street analyst forecast a $28 price target for Adverum Bio (ADVM) this month, up 277.87% from its last price of $7.41. Compared to the last 3 and 12 months, the average price target increased by 169.91% and increased by 169.91%, respectively.

Adverum Bio's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $489.75K (high $490K, low $489.5K), average EBITDA is $-97.946K (high $-97.896K, low $-97.996K), average net income is $-115M (high $-108M, low $-118M), average SG&A $13.36M (high $13.37M, low $13.35M), and average EPS is $-5.498 (high $-5.193, low $-5.65). ADVM's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-112M (high $-112M, low $-112M), average SG&A $0 (high $0, low $0), and average EPS is $-5.35 (high $-5.35, low $-5.35).

Based on Adverum Bio's last annual report (Dec 2019), the company's revenue was $250K, which missed the average analysts forecast of $1.22M by -79.44%. Apple's EBITDA was $-66.972M, beating the average prediction of $-17.105M by 291.53%. The company's net income was $-60.427M, missing the average estimation of $-194M by -68.91%. Apple's SG&A was $28.38M, missing the average forecast of $33.17M by -14.44%. Lastly, the company's EPS was $-0.94, missing the average prediction of $-11.203 by -91.61%. In terms of the last quarterly report (Mar 2021), Adverum Bio's revenue was $7.5M, beating the average analysts' forecast of $92K by 8052.17%. The company's EBITDA was $-27.27M, missing the average prediction of $-33.729M by -19.15%. Adverum Bio's net income was $-28.436M, missing the average estimation of $-35.171M by -19.15%. The company's SG&A was $16.16M, beating the average forecast of $2.51M by 544.04%. Lastly, the company's EPS was $-0.29, missing the average prediction of $-3.811 by -92.39%